Prolonging lung cancer response to EGFR inhibition by targeting the selective advantage of resistant cells
L. Brunet, D. Alexandre, J. Lee, M. d. M. Blanquer-Rossello, A. Guernet, H. Chhouri, Z. Kherrouche, A. Arabo, S. Yao, D. Godefroy, J. Dehedin, J.-R. Li, C. Duparc, P. Jamme, A. Vinchent, , L. Grumolato
This study shows that sorafenib can prolong lung cancer response to EGFR inhibitors by targeting resistant cells' selective advantage.
bioRxiv · Jun 19, 2023Cancer Biology